clement, Author at BaseLaunch

Features

Roche grabs a remyelination MS drug from Versant as the research team spins out into a $25M regenerative med startup

Roche grabs a remyelination MS drug from Versant The Versant research team spins out into a $25M regenerative med startup Nearly 4 years after Roche…

clement04.04.2018

Features

Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures

Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures Belldegrun didn’t just co-found a new biotech…

clement03.04.2018

John Mcconnico | Bloomberg | Getty Images A lab technician at Pharma Novo Nordisk conducts in vitro research in Malov, Denmark.

Features

Big Pharma’s billion-dollar scramble to invest in start-ups to fuel innovation

Big Pharma's billion-dollar scramble to invest in start-ups to fuel innovation The worldwide prescription drug market is growing at 6.5% compounded annually and is expected…

clement29.03.2018

Portfolio news

Biotech VCs are backing more rounds and making bigger bets

Biotech is a lot like venture capital. Vast amounts of research, testing and marketing go into a wide range of therapies. But in the end,…

clement10.03.2018

Features

BioMedPartners closes new venture capital fund

Basel-based venture capitalist firm BioMedPartners has closed its new venture capital fund BioMedInvest III at 100 million Swiss francs. The fund will help drive growth…

clement06.03.2018

Features

Startup Generation Bio builds alternative to potentially risky viral vectors

A gene therapy startup company The startup headed up by bigwigs and backed early on by Atlas has pulled in a mega-round of $100 million. The…

clement27.02.2018

Features

One year BaseLaunch healthcare accelerator program – Happy Birthday!

A short review A year ago, BaselArea.swiss presented BaseLaunch at a fully booked launch event in Basel, Switzerland. Guests from the healthcare industry, research, academia…

clement22.02.2018

Features

Targeted protein degraders are redefining how small molecules look and act

The new modality promises to open up the human proteome to drug developers, but first they will need to work out the rules When the…

clement19.02.2018

Features

Roche accelerates development of cancer treatments

The Basel-based pharma company Roche is to acquire the U.S. company Flatiron Health, which develops software solutions for use in oncology.

clement16.02.2018

Features

Santhera licenses Polyphor cystic fibrosis drug

The pharma company Santhera Pharmaceuticals has obtained the worldwide exclusive license for the product candidate POL6014. Developed by Polyphor, the drug has the potential to…

clement15.02.2018

clement

Roche grabs a remyelination MS drug from Versant as the research team spins out into a $25M regenerative med startup

Belldegrun teams with a group of top VC players to unveil a $295M biotech fund at Vida Ventures

Big Pharma’s billion-dollar scramble to invest in start-ups to fuel innovation

Biotech VCs are backing more rounds and making bigger bets

BioMedPartners closes new venture capital fund

Startup Generation Bio builds alternative to potentially risky viral vectors

One year BaseLaunch healthcare accelerator program – Happy Birthday!

Targeted protein degraders are redefining how small molecules look and act

Roche accelerates development of cancer treatments

Santhera licenses Polyphor cystic fibrosis drug

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us